secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2026-05-21T12:15:15+00:00
Accession:  0001193125-26-233507
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus appoints Nishant Saxena as first Chief Business Officer; schedules CRB-701 data call
--------------------------------------------------------------------------------

- Nishant Saxena appointed CBO; base salary $470K, 192,300 options and 58,300 RSUs as initial equity.
- Conference call on May 26 at 8:00 a.m. EDT to discuss updated Phase 1/2 CRB-701 data (data cut April 1).
- Upcoming milestones: initiation of registrational study of CRB-701 in second-line HNSCC and completion of CANYON-1 Phase 1b for CRB-913 (CB1 inverse agonist).
- Brent Pfeiffenberger granted 24,700 nonqualified options and 7,500 RSUs as initial board equity awards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526233507/0001193125-26-233507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526233507/crbp-20260519.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-233507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer